GMAB

Genmab A/S ADS

28.28

USD

GMAB Earnings Reports

Positive Surprise Ratio

GMAB beat 26 of 40 last estimates.

65%

Next Report

Date of Next Report

May 07, 2026

Estimate for Q1 26 (Revenue/ EPS)

$922.26M

$1.30

Implied change from Q4 25 (Revenue/ EPS)

-12.83%

-38.97%

Implied change from Q1 25 (Revenue/ EPS)

+28.99%

-57.38%

Genmab A/S ADS earnings per share and revenue

On Feb 18, 2026, GMAB reported earnings of 2.13 USD per share (EPS) for Q4 25, missing the estimate of 3.49 USD, resulting in a -39.11% surprise. Revenue reached 1.06 billion, compared to an expected 1.06 billion, with a 0.19% difference. The market reacted with a -0.23% price change (close before vs. close after earnings).

Looking ahead to Q1 26, 7 analysts forecast an EPS of 1.30 USD, with revenue projected to reach 922.26 million USD, implying an decrease of -38.97% EPS, and decrease of -12.83% in Revenue from the last quarter.

Industry Peers’ Earnings

Industry Peers' Earnings displays EPS earnings data from companies in the same industry. Click on a card to view more details.

Pharvaris N.V. Ordinary Shares

Report Date

Apr 02, 2026 For Q4 25

Estimate

-$0.63

Actual

-$0.72

Surprise

-13.69%

Nanobiotix S.A. - ADR

Report Date

Mar 31, 2026 For Q4 25

Estimate

$0.55

Actual

-$0.39

Surprise

-170.16%

Innate Pharma S.A. ADS

Report Date

Apr 01, 2026 For Q1 26

Estimate

-$0.12

Actual

-$0.55

Surprise

-353.80%

MiNK Therapeutics, Inc. Common Stock

Report Date

Mar 31, 2026 For Q4 25

Estimate

-$0.83

Actual

-$0.55

Surprise

+33.64%

Imunon, Inc. Common Stock

Report Date

Mar 31, 2026 For Q4 25

Estimate

-$1.19

Actual

-$1.99

Surprise

-66.18%

Kairos Pharma, Ltd.

Report Date

Mar 31, 2026 For Q4 25

Estimate

-$0.05

Actual

-$0.07

Surprise

-28.68%

Cadrenal Therapeutics, Inc. Common Stock

Report Date

Mar 31, 2026 For Q4 25

Estimate

-$1.18

Actual

-$1.43

Surprise

-20.34%

Soligenix, Inc. Common Stock

Report Date

Mar 31, 2026 For Q4 25

Estimate

-$0.57

Actual

-$0.28

Surprise

+50.98%

BioAtla, Inc. Common Stock

Report Date

Mar 31, 2026 For Q4 25

Estimate

-$12.24

Actual

-$8.00

Surprise

+34.64%

Sunshine Biopharma Inc.

Report Date

Apr 03, 2026 For Q4 25

Estimate

-$0.27

Actual

-$0.54

Surprise

-96.08%

FAQ

What were Genmab A/S ADS's earnings and revenue for the latest quarter Q4 2025?

For Q4 2025, Genmab A/S ADS reported EPS of $2.13, missing estimates by -39.11%, and revenue of $1.06B, 0.19% above expectations.

How did the market react to Genmab A/S ADS's Q4 2025 earnings?

The stock price moved down -0.23%, changed from $30.97 before the earnings release to $30.90 the day after.

When is Genmab A/S ADS expected to report next?

The next earning report is scheduled for May 07, 2026.

What are the forecasts for Genmab A/S ADS's next earnings report?

Based on 7 analysts, Genmab A/S ADS is expected to report EPS of $1.30 and revenue of $922.26M for Q1 2026.

Which companies are reporting earnings today?

Check FXEmpire's Earnings Calendar for today's list of reporting companies.